Adverse events
SECONDARY, ADVERSE EVENT, COMPLICATIONS
A secondary endpoint for the study is serious outcomes at 90 days, 1 and 2 years. This data will therefore be routinely collected as part of the study and not recorded as an adverse event (AE). Hospital admission will also not be recorded as an AE. The only AEs recorded will be those directly related to the use of initial ambulatory ECG recording both in the intervention and standard care groups. Participants will be asked through the automated monthly email/text questionnaire at month 2, whether they suffered any complications related to wearing any monitoring devices in the first 2 months of the trial.A Trial Steering Committee (TSC) will be established to oversee the conduct and progress of the trial. The details of the TSC will be captured in a separate charter. An independent Data Monitoring Committee (DMC) will be established to oversee the safety of participants in the trial. The details of the DMC will be captured in a separate charter.